Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials

• Published in: Cancer and metastasis reviews Vol. 29; no. 4; pp. 581 - 594
• Main Author: Markopoulos, Christos J.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.12.2010; Springer; Springer Nature B.V
• Subjects: Adjuvant treatment; Adjuvants; Antineoplastic Agents, Hormonal - therapeutic use; Aromatase; Aromatase Inhibitors - therapeutic use; Biological and medical sciences; biomarkers; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cancer; Cancer Research; Clinical trials; Female; Gynecology. Andrology. Obstetrics; Hormones; Humans; Mammary gland diseases; Medical sciences; Metastases; Metastasis; Mortality; Neoplasm Metastasis; Neoplasm Recurrence, Local - pathology; Neoplasms, Hormone-Dependent - drug therapy; Neoplasms, Hormone-Dependent - pathology; Non-Thematic Review; Oncology; Patient outcomes; Post-menopause; Postmenopausal women; Postmenopause; Prognosis; Reviews; Subpopulations; Surgery; Survival; Tamoxifen; Treatment Outcome; Tumors; Distant metastasis; Exemestane; Tamoxifen; Anastrozole; Letrozole; Aromatase inhibitors; Steroid; Antineoplastic agent; Relapse; Breast disease; Prognosis; Azole derivatives; Antiestrogen; Early stage; Antihormone; Estrogen synthase; Metastasis; Selective estrogen receptor modulator; Cancerology; Postmenopause; Clinical trial; Non steroid compound; Hormone; Aromatase inhibitor; Enzyme; Treatment efficiency; Enzyme inhibitor; Breast cancer; Malignant tumor; Androstane derivatives; Tamoxifene; Mammary gland diseases; Triazole derivatives; Bibliographic review; Cancer

Breast cancer is one of the leading causes of cancer-related deaths in women. Regardless of prognosis, all women with breast cancer are at risk for early recurrence. Nearly 50% of early recurrences occur within 5 years of surgery, and they peak at 2 years after surgery in women treated with adjuvant...